Vertex's triple CF combo meets in Phase III

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said one of its two cystic fibrosis triple combination therapies has met the primary endpoint of improving lung function in two Phase III trials. The company’s triple regimens have

Read the full 333 word article

User Sign In